{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:20:05Z","timestamp":1791357605078,"version":"4.3.1"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Addict"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Several medications for alcohol use disorder (MAUDs) are recommended to treat alcohol use disorder (AUD) in the Veterans Affairs (VA) guidelines. This study descriptively characterized treatment patterns and healthcare resource utilization (HCRU) among VA patients with AUD treated with VA\u2010recommended MAUDs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Veterans Health Administration data (VHA; 08\/01\/2013\u201311\/30\/2019) were used to identify 31,384 adults aged \u226518 years with AUD who initiated disulfiram (<jats:italic>n<\/jats:italic>\u2009=\u20092115), acamprosate (<jats:italic>n<\/jats:italic>\u2009=\u20093756), oral naltrexone (<jats:italic>n<\/jats:italic>\u2009=\u200925,082), or extended\u2010release naltrexone (XR\u2010NTX; <jats:italic>n<\/jats:italic>\u2009=\u2009431) following AUD diagnosis. Study measures, stratified by medication received, included treatment adherence (proportion of days covered), discontinuation, and HCRU over 1 year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean time to treatment discontinuation was high for all MAUDs but longest for XR\u2010NTX (92 vs. 55\u201359 days; all <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001). Relative to the year preceding AUD diagnosis, treatment with MAUDs was associated with fewer hospitalizations (XR\u2010NTX: 0.48 vs. 0.42; oral naltrexone: 0.58 vs. 0.47; acamprosate: 0.67 vs. 0.60; disulfiram: 0.63 vs. 0.57) and more outpatient visits per patient (XR\u2010NTX: 20.0 vs. 36.0; oral naltrexone: 19.0 vs. 30.0; acamprosate: 19.0 vs. 31.0; disulfiram: 17.0 vs. 29.0).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Among veterans with AUD, this descriptive analysis found that MAUD use was associated with reduced hospitalizations, and XR\u2010NTX was associated with a longer treatment duration versus oral MAUDs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Scientific Significance<\/jats:title><jats:p>This real\u2010world study is among the first to describe clinical characteristics, treatment patterns, and HCRU in VHA patients who initiated MAUDs when all MAUDs were included in the VHA formulary.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajad.70036","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:29:45Z","timestamp":1747096185000},"page":"536-546","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment patterns and healthcare resource use among veterans initiating medication for incident moderate\u2010to\u2010severe alcohol use disorder"],"prefix":"10.1111","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7235-7584","authenticated-orcid":false,"given":"Regina","family":"Grebla","sequence":"first","affiliation":[{"name":"Alkermes, Inc. Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa L.","family":"Kauf","sequence":"additional","affiliation":[{"name":"Alkermes, Inc. Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lax","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Cook","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilu","family":"Lin","sequence":"additional","affiliation":[{"name":"Southeast Louisiana Veterans Health Care System New Orleans Louisiana USA"},{"name":"Tulane University New Orleans Louisiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieruo","family":"Liu","sequence":"additional","affiliation":[{"name":"Alkermes, Inc. Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqian","family":"Liu","sequence":"additional","affiliation":[{"name":"Southeast Louisiana Veterans Health Care System New Orleans Louisiana USA"},{"name":"Tulane University New Orleans Louisiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"O'Sullivan","sequence":"additional","affiliation":[{"name":"Alkermes, Inc. Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizheng","family":"Shi","sequence":"additional","affiliation":[{"name":"Southeast Louisiana Veterans Health Care System New Orleans Louisiana USA"},{"name":"Tulane University New Orleans Louisiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Shi","sequence":"additional","affiliation":[{"name":"Groupe d'Analyse Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Alkermes, Inc. Waltham Massachusetts USA"},{"name":"Columbia University New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse","family":"Swallow","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1086-3067","authenticated-orcid":false,"given":"Katie","family":"Witkiewitz","sequence":"additional","affiliation":[{"name":"University of New Mexico Albuquerque New Mexico USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Drexler","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"National Institute on Alcohol Abuse and Alcoholism. Understanding alcohol use disorder. Accessed October 10 2021.https:\/\/wwwniaaa.nih.gov\/publications\/brochures-and-fact-sheets\/understanding-alcohol-use-disorder"},{"key":"e_1_2_8_3_1","unstructured":"Substance Abuse and Mental Health Services Administration (US). 2020 NSDUH Annual National Report.2020. Accessed March 31 2022.https:\/\/wwwsamhsa.gov\/data\/report\/2020-nsduh-annual-national-report"},{"issue":"6","key":"e_1_2_8_4_1","first-page":"457","article-title":"Medications for alcohol use disorder","volume":"93","author":"Winslow BT","year":"2016","journal-title":"Am Fam Physician"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2010.09.007"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.02.036"},{"key":"e_1_2_8_7_1","volume-title":"Incorporating Alcohol Pharmacotherapies Into Medical Practice, Treatment Improvement Protocol (TIP) Series, No. 49","author":"Substance Abuse and Mental Health Services Administration (US)","year":"2009"},{"key":"e_1_2_8_8_1","unstructured":"US Food and Drug Administration. Highlights of prescribing information: CAMPRAL\u00ae (acamprosate calcium). Accessed October 12 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021431s015lbl.pdf"},{"key":"e_1_2_8_9_1","volume-title":"Incorporating Alcohol Pharmacotherapies Into Medical Practice, Treatment Improvement Protocol (TIP) Series, No. 49","author":"Substance Abuse and Mental Health Services Administration (US)","year":"2009"},{"key":"e_1_2_8_10_1","volume-title":"Incorporating Alcohol Pharmacotherapies Into Medical Practice","author":"Substance Abuse and Mental Health Services Administration (US)","year":"2009"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15572"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.15288\/jsad.2019.80.572"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-016-0063-8"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.3387"},{"key":"e_1_2_8_15_1","unstructured":"Pharmacy Benefits Management\u2010 Medical Advisory Panel\u2010 VISN Pharmacist Executives. Ez \u2010 MINUTES.Posting of National PBM Documents.2014;12(3).https:\/\/www.pbm.va.gov\/linksotherresources\/ezminutes\/Ez_Minutes_Newsletter_Aug_Oct_2014.pdf"},{"key":"e_1_2_8_16_1","unstructured":"U.S. Government Accountability Office. VHA improved certain prescribing practices but needs to strengthen treatment plan oversight. GAO\u201019\u2010465.2019.https:\/\/www.gao.gov\/assets\/gao-19-465.pdf"},{"key":"e_1_2_8_17_1","unstructured":"The Management of Substance Use Disorders Work Group. VA\/DoD clinical practice guideline for the management of substance use disorders.2021.https:\/\/www.healthquality.va.gov\/guidelines\/MH\/sud\/VADoDSUDCPG.pdf"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/M21-4011"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/NAQ.0000000000000118"},{"key":"e_1_2_8_20_1","first-page":"222","article-title":"Extended\u2010release naltrexone for alcohol dependence: persistence and healthcare costs and utilization","volume":"17","author":"Bryson WC","year":"2011","journal-title":"Am J Manag Care"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201000553"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108764"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S116720"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2015.07.016"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2021.05.194"},{"key":"e_1_2_8_26_1","first-page":"222","article-title":"Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence","volume":"17","author":"Baser O","year":"2011","journal-title":"Am J Manag Care"},{"issue":"12","key":"e_1_2_8_27_1","first-page":"879","article-title":"Comparison of healthcare utilization among patients treated with alcoholism medications","volume":"16","author":"Mark TL","year":"2010","journal-title":"Am J Manag Care"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2020.04.003"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12786"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.12597"},{"key":"e_1_2_8_31_1","first-page":"597","article-title":"Implementation of evidence\u2010based alcohol screening in the Veterans Health Administration","volume":"12","author":"Bradley KA","year":"2006","journal-title":"Am J Manag Care"}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajad.70036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:05:08Z","timestamp":1757419508000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajad.70036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/ajad.70036"],"URL":"https:\/\/doi.org\/10.1111\/ajad.70036","archive":["Portico"],"relation":{},"ISSN":["1055-0496","1521-0391"],"issn-type":[{"value":"1055-0496","type":"print"},{"value":"1521-0391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"2024-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}